05.04.2013 - German Mologen AG has hired Alfredo Zurlo for the newly created position as Chief Medical Officer (CMO).
The oncologist, with more than 13 years of clinical expertise, take the post at the beginning of April. Dr Zurlo will be responsible for the clinical development of Mologen’s oncology candidate drugs MGN1703 and MGN1601. Zurlo has worked with Mologen as Senior Medical Advisor since 2012. Prior to that he worked for 8 years with Roche, as Medical Director of Oncology and Senior International Medical Leader.